Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinicopathological characteristics of study population

From: Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30

  2010–2015 dataset (n = 19,791) 2004–2009 dataset (n = 9346)
RS 18–25
[n = 15,731; No. (%)]
RS 26–30
[n = 4060; No. (%)]
P RS 18–25
[n = 7401; No. (%)]
RS 26–30
[n = 1945; No. (%)]
P
Year of diagnosis
 2004–2005   567 (7.7) 155 (8.0) 0.421
 2006–2007   2522 (34.1) 689 (35.4)  
 2008–2009   4312 (58.3) 1101 (56.6)  
 2010–2011 4748 (30.2) 1243 (30.6) 0.797  
 2012–2013 5229 (33.2) 1329 (32.7)   
 2014–2015 5754 (36.6) 1488 (36.7)   
Age at diagnosis (years)
 ≤ 50 3836 (24.4) 923 (22.7) 0.025 2340 (31.6) 539 (27.7) 0.003
 51–60 4924 (31.3) 1239 (30.5)   2456 (33.2) 654 (33.6)  
 61–70 4990 (31.7) 1378 (33.9)   1971 (26.6) 557 (28.6)  
 > 70 1981 (12.6) 520 (12.8)   634 (8.6) 195 (10.0)  
Race/ethnicity
 White 12,946 (82.3) 3263 (80.4) 0.018 6299 (85.1) 1662 (85.5) 0.737
 Black 1296 (8.2) 391 (9.6)   506 (6.8) 139 (7.2)  
 Other* 1405 (8.9) 386 (9.5)   561 (7.6) 137 (7.0)  
 Missing 84 (0.5) 20 (0.5)   35 (0.5) 7 (0.4)  
History of cancer
 No 13,960 (88.7) 3551 (87.5) 0.023 6654 (89.9) 1764 (90.7) 0.302
 Yes 1771 (11.3) 509 (12.5)   747 (10.1) 181 (9.3)  
Marital status
 Married 9819 (62.4) 2473 (60.9) 0.004 4924 (66.5) 1259 (64.7) 0.215
 Single 2105 (13.4) 630 (15.5)   885 (12.0) 255 (13.1)  
 Other 3078 (19.6) 786 (19.4)   1333 (18.0) 372 (19.1)  
 Missing 729 (4.6) 171 (4.2)   259 (3.5) 59 (3.0)  
Histologic type
 Ductal 11,490 (73.0) 3226 (79.5) < 0.001 5446 (73.6) 1556 (80.0) < 0.001
 Lobular 2251 (14.3) 391 (9.6)   897 (12.1) 161 (8.3)  
 Mixed ductal-lobular 1818 (11.6) 394 (9.7)   960 (13.0) 202 (10.4)  
 Other 172 (1.1) 49 (1.2)   98 (1.3) 26 (1.3)  
Tumor stage
 T1b 3535 (22.5) 801 (19.7) < 0.001 1789 (24.2) 409 (21.0) < 0.001
 T1c 8271 (52.6) 2112 (52.0)   4217 (57.0) 1070 (55.0)  
 T2 3698 (23.5) 1091 (26.9)   1339 (18.1) 446 (22.9)  
 T3 227 (1.4) 56 (1.4)   56 (0.8) 20 (1.0)  
Grade
 I 3774 (24.0) 486 (12.0) < 0.001 1795 (24.3) 251 (12.9) < 0.001
 II 8990 (57.2) 2087 (51.4)   4145 (56.0) 1007 (51.8)  
 III 2644 (16.8) 1434 (35.3)   1233 (16.7) 636 (32.7)  
 Missing 323 (2.1) 53 (1.3)   228 (3.1) 51 (2.6)  
ER/PR status
 +/+ 13,842 (88.0) 3164 (77.9) < 0.001 6389 (86.3) 1459 (75.0) < 0.001
 +/− 1872 (11.9) 885 (21.8)   993 (13.4) 478 (24.6)  
 −/+ 17 (0.1) 11 (0.3)   19 (0.3) 8 (0.4)  
Type of surgery
 Breast-conservation surgery 10,806 (68.7) 2747 (67.7) 0.207 5199 (70.3) 1326 (68.2) 0.076
 Mastectomy 4925 (31.3) 1313 (32.3)   2202 (29.8) 619 (31.8)  
Radiation therapy
 No or unknown 6268 (39.8) 1834 (45.2) < 0.001 3038 (41.1) 853 (43.9) 0.025
 Yes 9463 (60.2) 2226 (54.8)   4363 (59.0) 1092 (56.1)  
Chemotherapy
 No or unknown 11,832 (75.2) 1807 (44.5) < 0.001 5044 (68.2) 865 (44.5) < 0.001
 Yes 3899 (24.8) 2253 (55.5)   2357 (31.9) 1080 (55.5)  
  1. RS recurrence score, No. number, ER estrogen receptor, PR progesterone receptor
  2. *Other race includes American Indian, Alaska Native, and Asian or Pacific Islander
  3. Other marital status includes separated, divorced, and widowed categories